Inventiva SA (IVA), headquartered in Daix, France, is a clinical-stage biopharmaceutical company dedicated to advancing innovative oral small molecule therapies aimed at addressing significant unmet medical needs, particularly in non-alcoholic steatohepatitis (NASH) and mucopolysaccharidosis (MPS). With a robust pipeline of proprietary drug candidates targeting complex metabolic and rare diseases, Inventiva is well-positioned to enter pivotal clinical trials that could revolutionize treatment paradigms. The company's strategic focus on these high-impact therapeutic areas presents compelling opportunities for driving substantial value in the biopharmaceutical sector. Show more

Location: 50 RUE DE DIJON, DAIX, FRANCE, 21121, Daix, 21121, USA | Website: https://inventivapharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

557.3M

52 Wk Range

$2.23 - $7.98

Previous Close

$5.80

Open

$5.71

Volume

298,296

Day Range

$5.71 - $6.10

Enterprise Value

1.044B

Cash

122.1M

Avg Qtr Burn

-53.89M

Insider Ownership

0.00%

Institutional Own.

13.18%

Qtr Updated

03/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lanifibranor (Pan-PPAR) Details Metabolic dysfunction-associated steatohepatitis (MASH)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lanifibranor + empagliflozin Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cedirogant (ABBV-157) (60RORy) Details Psoriasis, Kidney cancer, Carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Odiparcil (GAG) Details Rare diseases, Rare genetic disease, Mucopolysaccharidoses, Mucopolysaccharidosis type IV, Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.